Figure 3. miR-34a enhances the antitumor effect of DADS in in mouse xenograft models.

(A) MDA-MB-231 cells were subcutaneously injected into nude mice. When the tumors were established, the effects of mock (an intraperitoneal injection of 100 µl PBS) and DADS (an intraperitoneal injection of 100 mg·kg⁻¹ DADS in PBS) treatment on tumor volume were examined every 4 days. Average tumor volumes are represented (n = 5 for each experimental group) starting from the first injection and continuing until sacrifice 28 days later. (B) After 28 days, the mice (from A) were euthanized, necropsies were performed, and tumors were weighed. All data are shown as the means±s.e.m. * p<0.05 vs. scramble. * p<0.05 vs. miR-34a. (C) MDA-MB-231 cells were subcutaneously injected into nude mice. When the tumors were established, the effects on tumor volume of intratumoral injections of scramble miRNA (40 µl negative control miRNA), miR-34a (40 µl of miR-34a mimics), or miR-22 (40 µl of miR-22 mimics) as well as a mock treatment (an intraperitoneal injection of 100 µl PBS plus an intratumoral injection of 40 µl negative control miRNA) and DADS+ miR-34a (an intraperitoneal injection of 100 mg·kg⁻¹ DADS plus an intratumoral injection of 40 µl miR-34a mimics) were examined every 4 days. Average tumor volumes (n = 5 for each experimental group) are represented starting from the first injection and continuing until sacrifice 28 days later. (D) After 28 days, the mice (from C) were euthanized, necropsies were performed, and tumors were weighed. All data are shown as the means±s.e.m. *p<0.05 vs. scramble. *p<0.05 vs. miR-34a.